Canagliflozin

(Difference between revisions)

Revision as of 08:24, 24 January 2024

↑ "Canagliflozin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.
↑ "Integrity - Clarivate"

@@ Line 1: / Line 1: @@
 <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1023629/Cv/1'>
 Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes.<ref name="a2">[https://www.drugs.com/monograph/canagliflozin.html "Canagliflozin Monograph for Professionals".] Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.</ref> See also [https://en.wikipedia.org/wiki/Canagliflozin Canagliflozin].
+Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (the remaining 10% is done by SGLT1). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine,<ref name="a34">[https://clarivate.com/products/biopharma/ "Integrity - Clarivate"]</ref> corresponding to 476 kilocalories. Additional water is eliminated by osmotic diuresis, resulting in a lowering of blood pressure.
+Canagliflozin also inhibits renal SGLT1, contributing to about 10% of daily urinary glucose excretion.[35][36]
+This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to other types of anti-diabetic drugs such as sulfonylurea derivatives and insulin.[37]
 [[8hdh]].